Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belantamab Mafodotin + DRd in Transplant-Ineligible NDMM
NCT05280275Phase 2Recruiting
- Sponsor
- Hellenic Society of Hematology
- Start
- Apr 2022
- Primary completion
- Mar 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of belantamab mafodotin in multiple myeloma (MM), sponsored by Hellenic Society of Hematology. Started Apr 2022; status: recruiting.
02
Drugs
belantamab mafodotin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05280275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05280275.